Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder

Journal of Psychiatric Research

Volumn 45, Issue 12, 2011, Pages 1639-1647

  Schennach Wolff, Rebecca ^a   Meyer, Sebastian ^a   Seemüller, Florian ^a   Jäger, Markus ^a   Schmauss, Max ^b   Laux, Gerd ^c   Pfeiffer, Herbert ^d   Naber, Dieter ^e   Schmidt, Lutz G ^f   Gaebel, Wolfgang ^g   Klosterkötter, Joachim ^h   Heuser, Isabella ⁱ   Maier, Wolfgang ^j   Lemke, Matthias R ^k   Rüther, Eckart ^l   Klingberg, Stefan ^m   Gastpar, Markus ⁿ   Möller, Hans Jürgen ^a   Riedel, Michael ^a,o  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b District Hospital Augsburg   (Germany)

^c Inn Salzach Hospital Wasserburg/Inn   (Germany)

^d KLINIKUM MÜNCHEN OST   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF BONN   (Germany)

^k Rheinische Kliniken   (Germany)

^l UNIVERSITY OF GÖTTINGEN   (Germany)

^m UNIVERSITY OF TÜBINGEN   (Germany)

ⁿ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^o Vinzenz von Paul Hospital   (Germany)

more..

Author keywords

Clinical implications; Early improvement; Predictors; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; TRANQUILIZER; ZIPRASIDONE;

ADULT; ARTICLE; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; RATING SCALE; REMISSION; SCHIZOPHRENIA; STRAUSS CARPENTER PROGNOSTIC SCALE; TREATMENT RESPONSE;

EID: 80355144499     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.07.014     Document Type: Article

References (55)

1. Addington J., Leriger E., Addington D. Symptom outcome 1 year after admission to an early psychosis program. Canadian Journal of Psychiatry 2003, 48(3):204-207.
2. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 2003, 60(12):1228-1235.
3. Alpert M., Diamond F., Weisenfreund J., Taleporos E., Friedhoff A.J. The neuroleptic hypothesis: study of the covariation of extrapyramidal and therapeutic drug effects. British Journal of Psychiatry 1978, 133:169-175.
4. Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Association, American Psychiatric Association, Washington DC.
5. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington DC.
6. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 2005, 162(3):441-449.
7. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin 2008, 34(6):1163-1171.
8. Brousse G., Meary A., Blanc O., Lancon C., Llorca P.M., Leboyer M. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. Journal of Psychiatric Research 2010, 179(1):12-18.
9. Case M., Stauffer V.L., scher-Svanum H., Conley R., Kapur S., Kane J.M., et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychological Medicine 2010, 1-10.
10. Chang Y.C., Lane H.Y., Yang K.H., Huang C.L. Optimizing early prediction for antipsychotic response in schizophrenia. Journal of Clinical Psychopharmacology 2006, 26(6):554-559.
11. Cording C. Conceptual aspects in development and implementation of basic psychiatric documentation. Psychiatrische Praxis 1998, 25(4):175-178.
12. Crespo-Facorro B., Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Pardo-Garcia G., et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research 2007, 41(8):659-666.
13. Delay J., Deniker P., Tardieu Y., Lemperiere Th Premiers essais de la reserpine. Press Medicale 1955, 63:663-665. [Ref Type: Magazine Article].
14. Doering S., Muller E., Kopcke W., Pietzcker A., Gaebel W., Linden M., et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Bulletin 1998, 24(1):87-98.
15. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. Journal of Clinical Psychiatry 2006, 67(11):1707-1712.
16. Francey S.M., Nelson B., Thompson A., Parker A.G., Kerr M., Macneil C., et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research 2010, 119(1-3):1-10.
17. Gaebel W., Riesbeck M., Wolwer W., Klimke A., Eickhoff M., von W.M., et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry 2007, 68(11):1763-1774.
18. Garner B., Berger G.E., Nicolo J.P., Mackinnon A., Wood S.J., Pariante C.M., et al. Pituitary volume and early treatment response in drug-naive first-episode psychosis patients. Schizophrenia Research 2009, 113(1):65-71.
19. Gasquet I., Haro J.M., Novick D., Edgell E.T., Kennedy L., Lepine J.P. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. International Clinical Psychopharmacology 2005, 20(4):199-205.
20. de Haan L., Nimwegen L., Amelsvoort T., Dingemans P., Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41(4):125-128.
21. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967, 6(4):278-296.
22. Haro J.M., Novick D., Suarez D., Ochoa S., Roca M. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32(5):1287-1292.
23. Jager M., Riedel M., Messer T., Laux G., Pfeiffer H., Naber D., et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. European Archives of Psychiatry and Clinical Neuroscience 2007, 257(1):47-53.
24. Jager M., Schmauss M., Laux G., Pfeiffer H., Naber D., Schmidt G., et al. Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study. European Psychiatry 2009.
25. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry 2005, 162(5):939-946.
26. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Journal of Psychiatric Research 1988, 23(1):99-110.
27. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 2008, 102(1-3):230-240.
28. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35(2):581-590.
29. Kokes R.F., Strauss J.S., Klorman R. Premorbid adjustment in schizophrenia. Part II. Measuring premorbid adjustment: the instruments and their development. Schizophrenia Bulletin 1977, 3(2):186-213.
30. Koutsouleris N., Meisenzahl E.M., Davatzikos C., Bottlender R., Frodl T., Scheuerecker J., et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Archives of General Psychiatry 2009, 66(7):700-712.
31. Lenior M.E., Dingemans P.M., Schene A.H., Linszen D.H. Predictors of the early 5-year course of schizophrenia: a path analysis. Schizophrenia Bulletin 2005, 31(3):781-791.
32. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 2005, 57(12):1543-1549.
33. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. Journal of Clinical Psychiatry 2007, 68(3):352-360.
34. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007, 32(9):1903-1910.
35. Levine S.Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry 2010, 68(1):86-92.
36. Lieberman J.A., Koreen A.R., Chakos M., Sheitman B., Woerner M., Alvir J.M., et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Journal of Clinical Psychiatry 1996, 9(57 Suppl.):5-9.
37. Lin C.H., Chou L.S., Lin C.H., Hsu C.Y., Chen Y.S., Lane H.Y. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. Journal of Clinical Psychiatry 2007, 68(10):1522-1527.
38. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplement 1987, 334:1-100.
39. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry 2005, 62(9):975-983.
40. Meisenzahl E.M., Koutsouleris N., Bottlender R., Scheuerecker J., Jager M., Teipel S.J., et al. Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophrenia Research 2008, 104(1-3):44-60.
41. Moller H.J., Scharl W., von Z.D. Prediction of therapeutic success in acute neuroleptic treatment: results of an empirical study of 243 inpatient-treated schizophrenic patients. Fortschritte der Neurologie-Psychiatrie 1985, 53(10):370-383.
42. Moller H.J., Schmid-Bode W., von Z.D. Prediction of long-term outcome in schizophrenia by prognostic scales. Schizophrenia Bulletin 1986, 12(2):225-234.
43. Moller H.J., Riedel M., Jager M., Wickelmaier F., Maier W., Kuhn K.U., et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. International Journal of Neuropsychopharmacology 2008, 11(7):985-997.
44. Moller H.J., Jager M., Riedel M., Obermeier M., Strauss A., Bottlender R. The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. European Archives of Psychiatry and Clinical Neuroscience 2010, 260(5):367-384.
45. Myrtek M., Foerster F. The law of initial value: a rare exception. Biological Psychology 1986, 22(3):227-237.
46. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 2001, 50(1-2):79-88.
47. Obermeier M., Mayr A., Schennach-Wolff R., Seemuller F., Moller H.J., Riedel M. Should the PANSS Be Rescaled?. Schizophrenia Bulletin 2009.
48. Palao D.J., Arauxo A., Brunet M., Marquez M., Bernardo M., Ferrer J., et al. Positive versus negative symptoms in schizophrenia: response to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994, 18(1):155-164.
49. A language and environment for statistical computing 2008, R Development Core Team, URL, Foundation for Statistical Computing, Vienna, Austria, [Ref Type: Computer Program]. http://www.R-project.org.
50. Seeman M.V. The role of estrogen in schizophrenia. Journal of Psychiatry and Neuroscience 1996, 21(2):123-127.
51. Siris S.G. Suicide and schizophrenia. Journal of Psychopharmacology 2001, 15(2):127-135.
52. Umbricht D.S., Wirshing W.C., Wirshing D.A., McMeniman M., Schooler N.R., Marder S.R., et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. Journal of Clinical Psychiatry 2002, 63(5):420-424.
53. Usall J., Suarez D., Haro J.M. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Journal of Psychiatric Research 2007, 153(3):225-231.
54. Guidelines for ATC classification and DDD assignment 2010, WHO Collaborating Centre for Drug Statistics Methodology, [Oslo. Ref Type: Data File]. 13th ed.
55. Wolwer W., Buchkremer G., Hafner H., Klosterkotter J., Maier W., Moller H.J., et al. German research network on schizophrenia-bridging the gap between research and care. European Archives of Psychiatry and Clinical Neuroscience 2003, 253(6):321-329.